David Colcher

City Of Hope National Medical Center — United States

Medicine · Health Sciences

59h-index12.3kcitations287works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(144), Radiopharmaceutical Chemistry and Applications(132), Glycosylation and Glycoproteins Research(43), HER2/EGFR in Cancer Research(34), Medical Imaging Techniques and Applications(23)

Publications285 total

Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors
Cancers·2025· 1 citedOpen Access
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma
Blood Advances·2024· 1 citedOpen Access
Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients
Nuclear Medicine Communications·2023· 5 citedOpen Access
Supplementary Table 1 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Supplementary Figure 2 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Supplementary Figure 1 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
2023Open Access
Supplementary Figure 1 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Supplementary Figure Legend from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Data from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Supplementary Figure Legend from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
2023Open Access
Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
2023Open Access
Supplementary Table 1 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Supplementary Figure 2 from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Data from Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
2023Open Access
Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
2023Open Access
Supplementary Video 2 from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
2023Open Access
Supplementary Video 2 from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
2023Open Access
Data from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Jeffrey Schlom(21), Andrew Raubitschek(10), John E. Shively(8), Patricia Horan Hand(6), Surinder K. Batra(6), José Miguel Esteban López-Jamar(5), Marianna Nuti(4), Martin W. Brechbiel(4), Otto A. Gansow(4), Paul J. Yazaki(4), Jorge A. Carrasquillo(4), Paul H. Sugarbaker(4), G Bryant(4), Steven M. Larson(4), Gabriela Pavlínková(4), Barbara J.M. Booth(4), George H. Hinkle(4), Stephen J. Forman(3), Mario Roselli(3), Diane E. Milenic(3)